Linked Life Data

20564075

Source:http://linkedlifedata.com/resource/pubmed/id/20564075

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
14
pubmed:dateCreated
2010-7-12
pubmed:abstractText
Growing evidence supports cognitive dysfunction associated with standard dose chemotherapy in breast cancer survivors. We determined the incidence, nature, and chronicity of cognitive dysfunction in a prospective longitudinal randomized phase 3 treatment trial for patients with T1-3, N0-1, M0 breast cancer receiving 5-fluorouracil, doxorubicin, and cyclophosphamide with or without paclitaxel.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0008-543X
pubmed:author
pubmed:copyrightInfo
Copyright (c) 2010 American Cancer Society.
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
116
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3348-56
pubmed:dateRevised
2011-3-25
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer.
pubmed:affiliation
The University of Texas M. D. Anderson Cancer Center, Section of Neuropsychology, Department of Neuro-Oncology, Houston, Texas 77230-1402, USA. jwefel@mdanderson.org
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III